A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)

NCT07350850 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

PCNSL
Primary Central Nervous System Lymphoma

Interventions

DRUG: Pirtobrutinib, Sintilimab, Rituximab, Methotrexate
DRUG: Standard of Care (Investigator Selected)

Sponsor

Tongji Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]